CALL US: 1-855-483-4325

A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies

Purpose

This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies (chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), anaplastic large cell lymphoma, transformed mycosis fungoides (MF), or Sezary Syndrome). Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.

Keywords

lymphoid malignancies, mycosis fungoides, relapsed, refractory, anaplastic large cell lymphoma

Principal Investigator

Nam H Dang, M.D.

Department

HEMATOLOGY AND ONCOLOGY

Contact Information

nam.dang@medicine.ufl.edu
3522737832

Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at CTSI-Studies-L@lists.ufl.edu.

Other Resources

  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams